
Ruea-Yea Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3655158/publications.pdf Version: 2024-02-01



RUEA-YEA HUANC

#	Article	IF	CITATIONS
1	Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncolmmunology, 2017, 6, e1249561.	4.6	252
2	LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget, 2015, 6, 27359-27377.	1.8	242
3	Genome-Wide Screen Identifies Genes Whose Inactivation Confer Resistance to Cisplatin in Saccharomyces cerevisiae. Cancer Research, 2005, 65, 5890-5897.	0.9	54
4	Elevated Expression of the Serine-Arginine Protein Kinase 1 Gene in Ovarian Cancer and Its Role in Cisplatin Cytotoxicity In Vitro. PLoS ONE, 2012, 7, e51030.	2.5	41
5	Small Ubiquitin-Related Modifier Pathway Is a Major Determinant of Doxorubicin Cytotoxicity in Saccharomyces cerevisiae. Cancer Research, 2007, 67, 765-772.	0.9	28
6	Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies. , 2020, 8, e001237.		17
7	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer. Oncolmmunology, 2019, 8, e1586042.	4.6	16
8	Dysregulation of Purine Nucleotide Biosynthesis Pathways Modulates Cisplatin Cytotoxicity in <i>Saccharomyces cerevisiae</i> . Molecular Pharmacology, 2008, 74, 1092-1100.	2.3	15
9	Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genetics, 2018, 14, e1007194.	3.5	15